Related Experiment Video
Updated: Jul 29, 2025

Facilitating the Analysis of Immunological Data with Visual Analytic Techniques
Published on: January 2, 2011
Bringing FAIRness to FDA data through visualization
1Stanley Manne Children's Research Institute, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA.
Abstract:
Improving representation and inclusion in clinical trials for new medicinal products has been a high priority for federal agencies for over 2 decades, but data to evaluate progress have been difficult to access. In this issue of Patterns, Carmeli et al. provide a novel approach to aggregating and visualizing existing data to improve transparency and research.
Related Concept Videos
Drug Regulation
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Modified Boxplots
However, the box plot does not tell the reader about outliers - values that lie far from the center of the data. We can modify the standard box and whisker plot to identify the outliers and visualize the actual spread of the data in a sample.
Initially, we calculate the adjusted...
Bioequivalence: Overview
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Kaplan-Meier Approach

